{"title":"POPULATION HEALTH VALUE OF BEING IN TARGET: RESULTS FROM THE CANADIAN MULTI-MORBIDITY MODEL FOR TYPE 2 DIABETES","authors":"I. Sobotka, L. Cipriano, D. Coyle, B. Shah","doi":"10.1016/j.jcjd.2023.10.342","DOIUrl":null,"url":null,"abstract":"Diabetes affects nearly 10% of Canadians, and can lead to many diabetes-related complications. Novel therapies purport to both improve control of diabetes and reduce the risk of these complications. Microsimulation modelling allows for the synthesis of multiple data sources for comparative effectiveness analysis related to a variety of correlated outcomes. However, existing type 2 diabetes models often use data that are decades old, are derived using non-representative clinical trial populations, or do not fully model vascular risk.","PeriodicalId":93918,"journal":{"name":"Canadian journal of diabetes","volume":"108 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian journal of diabetes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.jcjd.2023.10.342","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Diabetes affects nearly 10% of Canadians, and can lead to many diabetes-related complications. Novel therapies purport to both improve control of diabetes and reduce the risk of these complications. Microsimulation modelling allows for the synthesis of multiple data sources for comparative effectiveness analysis related to a variety of correlated outcomes. However, existing type 2 diabetes models often use data that are decades old, are derived using non-representative clinical trial populations, or do not fully model vascular risk.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
